Q3 2025 EPS Estimates for Bruker Co. (NASDAQ:BRKR) Reduced by Zacks Research

Bruker Co. (NASDAQ:BRKR) – Investment analysts at Zacks Research decreased their Q3 2025 earnings per share (EPS) estimates for Bruker in a research report issued on Wednesday, September 18th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $0.94 for the quarter, down from their prior forecast of $0.96. The consensus estimate for Bruker’s current full-year earnings is $2.61 per share.

Bruker (NASDAQ:BRKR) last released its earnings results on Tuesday, August 6th. The medical research company reported $0.52 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.52. The company had revenue of $800.70 million for the quarter, compared to analyst estimates of $799.44 million. Bruker had a net margin of 11.29% and a return on equity of 24.92%. The firm’s quarterly revenue was up 17.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.50 EPS.

A number of other brokerages have also weighed in on BRKR. Citigroup reduced their price target on Bruker from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Wednesday, July 10th. TD Cowen reduced their target price on Bruker from $74.00 to $72.00 and set a “hold” rating on the stock in a research report on Wednesday, August 7th. Jefferies Financial Group began coverage on Bruker in a report on Monday, June 3rd. They issued a “buy” rating and a $85.00 price target for the company. The Goldman Sachs Group cut their price objective on shares of Bruker from $72.00 to $60.00 and set a “sell” rating on the stock in a report on Tuesday, July 9th. Finally, Wells Fargo & Company initiated coverage on shares of Bruker in a report on Tuesday, August 27th. They issued an “overweight” rating and a $78.00 target price for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $81.40.

Bruker Stock Up 1.7 %

Shares of NASDAQ BRKR opened at $68.32 on Monday. The firm has a market cap of $9.93 billion, a P/E ratio of 24.84, a price-to-earnings-growth ratio of 2.31 and a beta of 1.18. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.75 and a current ratio of 1.65. Bruker has a 1 year low of $53.79 and a 1 year high of $94.86. The firm’s 50 day moving average price is $64.68 and its 200 day moving average price is $72.30.

Hedge Funds Weigh In On Bruker

Several hedge funds and other institutional investors have recently made changes to their positions in BRKR. First Horizon Advisors Inc. raised its position in Bruker by 120.4% in the second quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 218 shares during the period. Rise Advisors LLC acquired a new position in Bruker during the 1st quarter worth approximately $27,000. Neo Ivy Capital Management purchased a new position in Bruker in the 4th quarter worth approximately $30,000. Covestor Ltd grew its position in Bruker by 139.1% in the first quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 210 shares in the last quarter. Finally, Principal Securities Inc. purchased a new stake in shares of Bruker during the fourth quarter valued at approximately $42,000. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Monday, September 2nd were given a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.29%. The ex-dividend date of this dividend was Friday, August 30th. Bruker’s payout ratio is currently 7.27%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.